Catalyst
Slingshot members are tracking this event:
Catalyst Biosciences (CBIO) receives regulatory guidance for Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
CBIO |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 06, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Marzaa, Hemophilia A, Hemophilia B